NCT07205081View on ClinicalTrials.gov

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Normal VolunteersAtopic Dermatitis (AD)Atopic EczemaAtopic Eczema/Dermatitis (Non-Specific)
Interventions
DRUG

ATTO-3712

ATTO-3712

DRUG

Placebo

Placebo preparation to match ATTO-3712 dose

Trial Locations (1)

H3P 3P1

Altasciences, Montreal

Sponsors
All Listed Sponsors
lead

Attovia Therapeutics Inc

INDUSTRY

NCT07205081 - Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter